Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli.

Rodríguez-Baño J, Oteo J, Ortega A, Villar M, Conejo MC, Bou G, Aranzamendi-Zaldumbide M, Cercenado E, Gurguí M, Martínez-Martínez L, Merino M, Rivera A, Oliver A, Weber I, Pascual A, Bartolomé RM, Gónzalez-López JJ, Campos J.

J Clin Microbiol. 2013 Jul;51(7):2414-7. doi: 10.1128/JCM.00999-13. Epub 2013 May 1.


Inhibitor-resistant TEM- and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates.

Oteo J, González-López JJ, Ortega A, Quintero-Zárate JN, Bou G, Cercenado E, Conejo MC, Martínez-Martínez L, Navarro F, Oliver A, Bartolomé RM, Campos J; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2014 Jul;58(7):3874-81. doi: 10.1128/AAC.02738-13. Epub 2014 Apr 28.


De-escalation for amoxicillin-susceptible Escherichia coli: easier said than done.

Donaldson AD, Barkham T.

J Hosp Infect. 2010 Mar;74(3):304-5. doi: 10.1016/j.jhin.2009.07.013. Epub 2009 Sep 25. No abstract available.


Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli.

Ortega A, Oteo J, Aranzamendi-Zaldumbide M, Bartolomé RM, Bou G, Cercenado E, Conejo MC, González-López JJ, Marín M, Martínez-Martínez L, Merino M, Navarro F, Oliver A, Pascual A, Rivera A, Rodríguez-Baño J, Weber I, Aracil B, Campos J.

Antimicrob Agents Chemother. 2012 Jul;56(7):3576-81. doi: 10.1128/AAC.06393-11. Epub 2012 Apr 9.


Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.

Lagacé-Wiens PR, Nichol KA, Nicolle LE, DeCorby M, McCracken M, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2006 Jun;57(6):1262-3. Epub 2006 Mar 24. No abstract available.


Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain.

Oteo J, Campos J, Lázaro E, Cuevas O, García-Cobos S, Pérez-Vázquez M, de Abajo FJ; Spanish Members of EARSS.

Emerg Infect Dis. 2008 Aug;14(8):1259-62. doi: 10.3201/eid1408.071059.


[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].

de Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual A.

Enferm Infecc Microbiol Clin. 2006 Dec;24(10):613-6. Spanish.


Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.

Fernandez-Cuenca F, Martinez-Martinez L, Amblar G, Biedenbach DJ, Jones RN, Pascual A.

Clin Microbiol Infect. 2006 Feb;12(2):197-8. No abstract available.


Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.

Kaye KS, Gold HS, Schwaber MJ, Venkataraman L, Qi Y, De Girolami PC, Samore MH, Anderson G, Rasheed JK, Tenover FC.

Antimicrob Agents Chemother. 2004 May;48(5):1520-5.


β-Lactamases in amoxicillin-clavulanate-resistant Escherichia coli strains isolated from a Chinese tertiary hospital.

Ding J, Ma X, Chen Z, Feng K.

Diagn Microbiol Infect Dis. 2013 Aug;76(4):532-3. doi: 10.1016/j.diagmicrobio.2013.04.015. Epub 2013 May 29.


[Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].

Martín-Pozo A, Alós JI.

Rev Esp Quimioter. 2012 Sep;25(3):222-3. Spanish. No abstract available.


Population analysis and epidemiological features of inhibitor-resistant-TEM-beta-lactamase-producing Escherichia coli isolates from both community and hospital settings in Madrid, Spain.

Martín O, Valverde A, Morosini MI, Rodríguez-Domínguez M, Rodríguez-Baños M, Coque TM, Cantón R, del Campo R.

J Clin Microbiol. 2010 Jul;48(7):2368-72. doi: 10.1128/JCM.00608-10. Epub 2010 May 5.


Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.

Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, Mentré F, Wolff M, Denamur E, Branger C; COLIBAFI Group.

Clin Microbiol Infect. 2011 Apr;17(4):557-65. doi: 10.1111/j.1469-0691.2010.03298.x.


Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.

Arch Intern Med. 2008 Sep 22;168(17):1897-902. doi: 10.1001/archinte.168.17.1897.


Susceptibility testing of Escherichia coli isolates from urines: are we at risk of reporting false antibiotic resistance to co-amoxiclav?

Bond A, Plumb H, Turner P.

J Antimicrob Chemother. 2012 Jun;67(6):1557-8. doi: 10.1093/jac/dks034. Epub 2012 Feb 14. No abstract available.


Multidrug-resistant Escherichia coli bacteremia.

Alhashash F, Weston V, Diggle M, McNally A.

Emerg Infect Dis. 2013 Oct;19(10):1699-701. doi: 10.3201/eid1910.130309. No abstract available.


Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.

Borsari AG, Bucher B, Brazzola P, Simonetti GD, Dolina M, Bianchetti MG.

Clin Ther. 2008 Nov;30(11):2090-5. doi: 10.1016/j.clinthera.2008.11.002.


Urinary tract pathogens and resistance pattern.

Chakupurakal R, Ahmed M, Sobithadevi DN, Chinnappan S, Reynolds T.

J Clin Pathol. 2010 Jul;63(7):652-4. doi: 10.1136/jcp.2009.074617. Epub 2010 May 24.


Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.

Docobo-Pérez F, Fernández-Cuenca F, Pachón-Ibáñez ME, Pascual A, Pichardo C, Martínez-Martínez L, Pachón J.

Clin Microbiol Infect. 2008 Jun;14(6):582-7. doi: 10.1111/j.1469-0691.2008.01948.x. Epub 2008 Feb 22.


Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality.

Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, Shih YC, Lin HH, Wang JL.

Antimicrob Agents Chemother. 2012 Feb;56(2):618-22. doi: 10.1128/AAC.05753-11. Epub 2011 Nov 28.

Supplemental Content

Support Center